-- 
Leumi, Fundtech, Teva, Mizrahi, Ophir: Israel Equity Preview

-- B y   S h a r o n   W r o b e l
-- 
2011-07-10T06:24:22Z

-- http://www.bloomberg.com/news/2011-07-10/leumi-fundtech-teva-mizrahi-ophir-israel-equity-preview.html
The following stocks may rise or
fall in Israeli markets. Stock symbols are in parentheses after
the company names and prices are from the last close unless
otherwise stated.  The TA-25 Index jumped 1.7 percent to 1,260.16 in Tel Aviv.  Bank Leumi  Le-Israel Ltd. (LUMI IT): The country’s largest
lender by assets, has postponed discussions on buying a stake in
Tnuva Marketing Cooperative, Israel’s biggest food producer,
until Aug. 31 as consumers protest the cost of cottage cheese.  “We have not decided if we are to continue or not,” Chief
Executive Officer Galia Maor said in an interview during a
conference in London on July 7. Bank Leumi rose 2.8 percent to
16.55 shekels.  Fundtech Ltd. (FNDT)  : The provider of software to
financial institutions was cut to “neutral” from “buy” at DA
Davidson & Co., with a 12-month price estimate of $20.50 per
share. Fundtech advanced 0.4 percent to 68.23 shekels.  Mizrahi Tefahot Bank Ltd. (MZTF)  : The Israeli lender
raised gross proceeds of 1.15 billion shekels ($338 million)
from a bond sale. Mizrahi gained 1.2 percent to 36.20 shekels.        Ophir Optronics Ltd. (OPIR)  : Newport Corp. (NEWP US) has
signed a definitive agreement to buy the maker of optical
instruments for $8.43 per share, or a total of about $230
million in cash. Ophir rose 0.6 percent to 14.93 shekels.  Unitronics (UNIT)  Ltd: The maker of automated systems
said it signed an agreement to purchase property in Modiin,
Israel for 17.4 million shekels. Unitronics dropped 4 percent to
15.92 shekels.  Teva Pharmaceutical Industries Ltd. (TEVA)  : The world’s
biggest generic-drug company agreed that it won’t sell generic
versions of the cholesterol drugs Vytorin and Zetia until April
25, 2017, settling patent lawsuits with Merck & Co., court
records show. Teva gained 0.8 percent to 167.80 shekels.  To contact the reporter on this story:
Sharon Wrobel in  Tel Aviv  at 
 swrobel4@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  